MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 12-16-2024
Enzo Biochem Interest Expense 2011-2026 | ENZ
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Enzo Biochem
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 494 K | 380 K | -178 K | 6.9 M | 488 K | 382 K | 168 K | 125 K | 122 K | 95 K | 194 K | -54 K | 21 K | 11 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.9 M | -178 K | 654 K |
Quarterly Interest Expense Enzo Biochem
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123 K | - | -726 K | -893 K | 158 K | - | 36 K | -63 K | -72 K | - | -716 K | 16 K | -145 K | 33 K | -88 K | 72 K | 17 K | 199 K | 17 K | 132 K | 127 K | 179 K | 70 K | 33 K | 47 K | 69 K | 47 K | 24 K | 36 K | 143 K | 36 K | 11 K | 119 K | 65 K | 119 K | -17 K | 54 K | 2 K | 54 K | 15 K | 19 K | 76 K | 19 K | 43 K | 61 K | 56 K | 61 K | 65 K | 9 K | 76 K | 9 K | 62 K | 9 K | 76 K | 9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 199 K | -893 K | -327 |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
367 | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Castle Biosciences
CSTL
|
1 K | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
177 M | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M |  China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Fulgent Genetics
FLGT
|
561 K | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 166.96 | 0.54 % | $ 28.7 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Interpace Biosciences
IDXG
|
-394 K | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Agilent Technologies
A
|
81 M | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
CareDx, Inc
CDNA
|
524 K | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Natera
NTRA
|
9.32 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 1.39 | 4.51 % | $ 417 M | USA |
 |
RadNet
RDNT
|
32.1 M | $ 61.74 | 0.41 % | $ 4.64 B | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |